Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyowa Hakko Launches Line of L-Citrulline Health Foods
September 17, 2007
- Blopress Maintains Top Position in 2nd Qtr: IMS Japan
September 17, 2007
- Hearings Completed for New Vision for Medical Devices Industry
September 17, 2007
- TOPICS／Seminar Aimed at Employment of Female MRs Attracts 300 Participants
September 17, 2007
- NEW PRODUCST
September 17, 2007
- Taiyo's Tablet Production Capacity Up to 8.5 Bil. Per Year
September 17, 2007
- JPA Leaders Exchange Opinions with New Health Minister
September 17, 2007
- BUSINESS NEWS IN BRIEF
September 17, 2007
- JPA Would Like to Expand the Role of Pharmacists
September 17, 2007
- No Reduction in Technical Fees Considered: New Health Minister
September 17, 2007
- Med. Fee Curtailment Policy Caused Collapse of Med. Insurance System: 3 Social Insurance Unions
September 17, 2007
- Korosho to Shift Priority from Treatment of ADRs to Prevention
September 17, 2007
- TOPICS／JADEC, sanofi-aventis Hold HbA1c Awareness Promotion Campaign
September 17, 2007
- NEW PRODUCTS／Daiichi Sankyo: Fentanyl for Infants
September 10, 2007
- RIKEN Kobe Institute to Develop
September 10, 2007
- Takeshi Erikawa Appointed
September 10, 2007
- Korosho to Train Senior CRCs, Data Managers, IRB Members
September 10, 2007
- Korosho to Demand \22,160.4 Bil., Up 3.2%, in FY2008
September 10, 2007
- Korosho to Standardize Forms for Clinical Trial Documents
September 10, 2007
- Japan's 1st Drug for ADHD Recommended for Approval
September 10, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…